Most Recent Articles by Lauren Burke
The FDA has granted alectinib (ALECENSA) accelerated approval for the treatment of patients with non-small cell lung cancer.
Using a genotype-guided dose of fluoropyrimidine in DPYD*2A variant allele carriers significantly reduced grade 3 or higher toxicities.
As of 2012 in the U.S. there were 14 million cancer survivors, a number that is expected to grow to 18 million by 2022.
The FDA announced approval of CYRAMZA (ramucirumab) for use in combination with FOLFIRI for metastatic colorectal cancer.
POMALYST for relapsed/refractory multiple myeloma has met its accelerated approval requirements.
More Articles by Lauren Burke
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Phase 2 Trial of Apatorsen for Metastatic Pancreatic Cancer Misses Primary Endpoint
- Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients
- Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs
- Tibetan Yoga May Improve Chemotherapy-related Fatigue
- Sequence of Sunitinib and Nephrectomy May Not Affect Progression-free Rate in mRCC